Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.

Diabetic medicine : a journal of the British Diabetic Association - 1 Apr 2009

Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley A T

Abstract excerpt

BACKGROUND AND AIMS: Hepatocyte nuclear factor-1 alpha (HNF1A) gene mutations are the commonest cause of monogenic diabetes, but patients are often misdiagnosed as having Type 1 diabetes and started on insulin treatment. Patients with HNF1A diabetes are particularly sensitive to the glucose-lowering effect of sulphonylureas, which are the pharmacological treatment of choice. We aimed to assess if patients do...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Diabetes Mellitus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatocyte Nuclear Factor 1-alpha

Share to Hypoglycemic Agents

Share to Insulin

Share to Mutation

Share to Practice Guidelines as Topic

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 19388975
DOI: 10.1111/j.1464-5491.2009.02690.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.PMID 19388975Read ↗

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metforminSemantic proximity Read ↗

Treatment of young patients with HNF1A mutations (HNF1A-MODY).Semantic proximity Read ↗

Systematic Review of Treatment of Beta-Cell Monogenic DiabetesSemantic proximity Read ↗

Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia.Semantic proximity Read ↗

Our evolving understanding of monogenic diabetes: possibilities of improving glycaemic control following transfer from insulin to sulphonylureas.Semantic proximity Read ↗

Mother and daughter carrying the same KCNJ11 mutation but with a different response to switching from insulin to sulfonylurea.Semantic proximity Read ↗

Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.Semantic proximity Read ↗

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.Semantic proximity Read ↗

Successful switch from insulin to oral sulfonylurea therapy in HNF1A-MODY Tunisian patient with the P291fsinsC mutation.Semantic proximity Read ↗

Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes.Semantic proximity Read ↗

Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.Semantic proximity Read ↗

Mexican Carriers of the HNF1A p.E508K Variant Do Not Experience an Enhanced Response to Sulfonylureas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.